Kiromic Biopharma Executives
KRBPDelisted Stock | USD 2.68 0.07 2.55% |
Kiromic Biopharma employs about 31 people. The company is managed by 5 executives with a total tenure of roughly 73 years, averaging almost 14.0 years of service per executive, having 6.2 employees per reported executive. Discussion of Kiromic Biopharma's management performance can provide insight into the enterprise performance.
Kiromic |
Kiromic Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.9194) % which means that it has lost $0.9194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.2981) %, meaning that it created substantial loss on money invested by shareholders. Kiromic Biopharma's management efficiency ratios could be used to measure how well Kiromic Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Kiromic Biopharma Workforce Comparison
Kiromic Biopharma is rated second overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 270. Kiromic Biopharma retains roughly 31.0 in number of employees claiming about 11% of equities under Health Care industry.
Kiromic Biopharma Notable Stakeholders
A Kiromic Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kiromic Biopharma often face trade-offs trying to please all of them. Kiromic Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kiromic Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Ryan | Chief Officer | Profile | |
Leonardo Mirandola | Chief Officer | Profile | |
JD CPA | CEO Director | Profile | |
Daniel Clark | Chief Officer | Profile | |
MD PharmD | Chief Staff | Profile |
About Kiromic Biopharma Management Performance
The success or failure of an entity such as Kiromic Biopharma often depends on how effective the management is. Kiromic Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kiromic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kiromic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Kiromic Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.
Kiromic Biopharma Workforce Analysis
Traditionally, organizations such as Kiromic Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kiromic Biopharma within its industry.Kiromic Biopharma Manpower Efficiency
Return on Kiromic Biopharma Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 6.9M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |